Dr Daniel Gale

Job title

Clinician scientist and honorary consultant nephrologist



GMC Number


Contact details

Email address: daniel.gale@nhs.net


Daniel Gale runs the Family Kidney Clinic that specialises in the care of families with inherited kidney problems, including polycystic kidney disease and alport syndrome. His research group aims to identify the genes causing kidney disease in families and to develop new ways to diagnose and treat them.


  • Adam, J., Connor, T. M. F., Wood, K., Lewis, D., Naik, R., Gale, D.P., & Sayer, J.A. (2014). Genetic testing can resolve diagnostic confusion in Alport syndrome Clin Kidney J , 7 (2): 197-200
  • Gale, D. P., & Maxwell, P. H. (2013). C3 glomerulonephritis and CFHR5 nephropathy. Nephrol Dial Transplant, 28 (2), 282-288. doi:10.1093/ndt/gfs441
  • Deltas, C., Gale, D., Cook, T., Voskarides, K., Athanasiou, Y., & Pierides, A. (2013). C3 Glomerulonephritis/CFHR5 Nephropathy Is an Endemic Disease in Cyprus: Clinical and Molecular Findings in 21 Families. Adv Exp Med Biol, 734, 189-196. doi:10.1007/978-1-4614-4118-2_12
  • Pickering, M. C., D'Agati, V. D., Nester, C. M., Smith, R. J., Haas, M., Appel, G. B., . . . Cook, H. T. (2013). C3 glomerulopathy: consensus report. Kidney Int. doi:10.1038/ki.2013.377
  • Voskarides, K., Demosthenous, P., Papazachariou, L., Arsali, M., Athanasiou, Y., Zavros, M., . . . Deltas, C. (2013). Epistatic role of the MYH9/APOL1 region on familial hematuria genes. PLoS One, 8 (3), e57925-?. doi:10.1371/journal.pone.0057925
  • Gale, D. P. (2013). How benign is hematuria? Using genetics to predict prognosis. Pediatr Nephrol, 28 (8), 1183-1193. doi:10.1007/s00467-012-2399-y
  • Connor, T. M., Oygar, D. D., Gale, D. P., Steenkamp, R., Nitsch, D., Neild, G. H., & Maxwell, P. H. (2013). Incidence of end-stage renal disease in the Turkish-Cypriot population of Northern Cyprus: a population based study. PLoS One, 8 (1), e54394-?. doi:10.1371/journal.pone.0054394
  • Formenti, F., Beer, P. A., Croft, Q. P., Dorrington, K. L., Gale, D. P., Lappin, T. R., . . . Robbins, P. A. (2011). Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation. FASEB J, 25 (6), 2001-2011. doi:10.1096/fj.10-177378
  • Bond, J., Gale, D. P., Connor, T., Adams, S., de Boer, J., Gascoyne, D. M., . . . Ancliff, P. J. (2011). Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood, 117 (13), 3699-3701. doi:10.1182/blood-2010-12-327569
  • Athanasiou, Y., Voskarides, K., Gale, D. P., Damianou, L., Patsias, C., Zavros, M., . . . Deltas, C. (2011). Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol, 6 (6), 1436-1446. doi:10.2215/CJN.09541010
  • International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret, G. B., Munroe, P. B., Rice, K. M., Bochud, M., Johnson, A. D., . . . Johnson, T. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 478 (7367), 103-109. doi:10.1038/nature10405
  • Vernon, K. A., Gale, D. P., de Jorge, E. G., McLean, A. G., Galliford, J., Pierides, A., . . . Cook, H. T. (2011). Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant, 11 (1), 152-155. doi:10.1111/j.1600-6143.2010.03333.
  • Gale, D. P., & Pickering, M. C. (2011). Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech, 4 (6), 721-726. doi:10.1242/dmm.008052
  • Gale, D. P. (2011). The identification of CFHR5 nephropathy. J R Soc Med, 104 (5), 186-190. doi:10.1258/jrsm.2011.11k013
  • Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., . . . Choi, P. (2010). Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 95 (3), 505-508. doi:10.3324/haematol.2009.013136
  • Chambers, J. C., Zhang, W., Lord, G. M., van der Harst, P., Lawlor, D. A., Sehmi, J. S., Gale, D.P.,. . . Kooner, J. S. (2010). Genetic loci influencing kidney function and chronic kidney disease. Nat Genet, 42 (5), 373-375. doi:10.1038/ng.566
  • Feehally, J., Farrall, M., Boland, A., Gale, D. P., Gut, I., Heath, S., . . . Ratcliffe, P. J. (2010). HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol, 21 (10), 1791-1797. doi:10.1681/ASN.2010010076
  • Gale, D. P., de Jorge, E. G., Cook, H. T., Martinez-Barricarte, R., Hadjisavvas, A., McLean, A. G., . . . Pickering, M. C. (2010).Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet, 376 (9743), 794-801. doi:10.1016/S0140-6736(10)60670-8
  • Vernon, K. A., Gale, D. P., de Jorge, E. G., McLean, A. G., Maxwell, P. H., Pickering, M. C., & Cook, H. T. (2010). Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. MOLECULAR IMMUNOLOGY, 47 (13), 2202. PERGAMON-ELSEVIER SCIENCE LTD. doi:10.1016/j.molimm.2010.05.024
  • Gale, D. P., & Maxwell, P. H. (2010). The role of HIF in immunity. Int J Biochem Cell Biol, 42 (4), 486-494. doi:10.1016/j.biocel.2009.10.012
  • Lou, T., Zhang, J., Gale, D. P., Rees, A. J., Rhodes, B., Feehally, J., . . . Maxwell, P. H. (2010). Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. Nephrol Dial Transplant, 25 (7), 1-?. doi:10.1093/ndt/gfq312
  • Formenti, F., Beer, P., Croft, Q. P. P., Dorrington, K. L., Gale, D. P., Lappin, T. R. J., . . . Robbins, P. A. (2009). A 'GAIN-OF-FUNCTION' MUTATION IN THE HYPOXIA-INDUCIBLE FACTOR 2 alpha GENE DOES NOT REDUCE EXERCISE CAPACITY IN HUMANS. J PHYSIOL SCI, 59, 357.
  • Gale, D. P., & Maxwell, P. H. (2009). Adaptation a l'hypoxie. In N. Casadevall, C. Gisselbrecht, J. Rossert (Eds.), Les agents stimulant l'érythropoïèse. John Libbey Eurotext.
  • Busbridge, M., Griffiths, C., Ashby, D., Gale, D., Jayantha, A., Sanwaiya, A., & Chapman, R. S. (2009). Development of a novel immunoassay for the iron regulatory peptide hepcidin. BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 66 (3), 150-157.
  • Busbridge, M., Ashby, D., Gale, D. P., Chapman, R., Patrick, M., & Bloom, S. (2009). Erythropoietin therapy leads to a reduction in hepcidin in chronic renal disease patients. CLINICAL CHEMISTRY, 55 (6), A169. AMER ASSOC CLINICAL CHEMISTRY.
  • Volke, M., Gale, D. P., Maegdefrau, U., Schley, G., Klanke, B., Bosserhoff, A. K., . . . Warnecke, C. (2009). Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS One, 4 (11), e7875. doi:10.1371/journal.pone.0007875
  • Ashby, D. R., Gale, D. P., Busbridge, M., Maxwell, P. H., & Choi, P. (2009). Hepcidin levels in patients with renal disease Response. KIDNEY INT, 76 (6), 680-681. doi:10.1038/ki.2009.240
  • Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., . . . Choi, P. (2009). Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. KIDNEY INT, 75 (9), 976-981. doi:10.1038/ki.2009.21
  • Gale, D. P., Harten, S. K., Reid, C. D., Tuddenham, E. G., & Maxwell, P. H. (2008). Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood, 112 (3), 919-921. doi:10.1182/blood-2008-04-153718
  • Pepper, R. J., Gale, D. P., Wajed, J., Bommayya, G., Ashby, D., McLean, A., . . . Maxwell, P. H. (2007). Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodial Int, 11 (4), 430-434. doi:10.1111/j.1542-4758.2007.00213.x
  • Gale, D. P., Cobbold, J. F., & Chataway, J. (2006). Steroid-responsive functional B12 deficiency in association with transcobalamin II polymorphism 776C --> G. Eur J Haematol, 76 (1), 75-78. doi:10.1111/j.1600-0609.2005.00563.